Oppenheimer Holdings, Inc. upgraded shares of TherapeuticsMD Inc (NYSEMKT:TXMD) from a market perform rating to an outperform rating in a report published on Tuesday, July 11th, StockTargetPrices.com reports.

TXMD has been the subject of a number of other research reports. Cantor Fitzgerald restated an overweight rating on shares of TherapeuticsMD in a report on Monday, April 17th. Stifel Nicolaus restated a buy rating and set a $20.00 price objective on shares of TherapeuticsMD in a report on Thursday, May 25th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company has an average rating of Buy and a consensus target price of $21.08.

TherapeuticsMD (NYSEMKT TXMD) traded down 1.14% during trading on Tuesday, hitting $5.20. 2,580,526 shares of the company traded hands. The stock has a 50 day moving average price of $5.36 and a 200 day moving average price of $5.53. The company’s market capitalization is $1.06 billion. TherapeuticsMD has a 12-month low of $3.50 and a 12-month high of $8.30.

TRADEMARK VIOLATION WARNING: “TherapeuticsMD Inc (NYSEMKT:TXMD) Upgraded to “Outperform” by Oppenheimer Holdings, Inc.” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/07/therapeuticsmd-inc-nysemkttxmd-upgraded-by-oppenheimer-holdings-inc-to-outperform-updated-updated-updated.html.

A number of hedge funds have recently bought and sold shares of the stock. State Street Corp increased its stake in shares of TherapeuticsMD by 9.1% in the fourth quarter. State Street Corp now owns 3,650,254 shares of the specialty pharmaceutical company’s stock worth $21,064,000 after buying an additional 303,633 shares during the last quarter. Raymond James Financial Services Advisors Inc. bought a new stake in shares of TherapeuticsMD during the fourth quarter worth approximately $106,000. Guggenheim Capital LLC increased its stake in shares of TherapeuticsMD by 135.9% in the fourth quarter. Guggenheim Capital LLC now owns 36,290 shares of the specialty pharmaceutical company’s stock worth $209,000 after buying an additional 20,904 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of TherapeuticsMD by 20.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 22,150 shares of the specialty pharmaceutical company’s stock worth $128,000 after buying an additional 3,740 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of TherapeuticsMD during the fourth quarter worth approximately $8,261,000.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Stock Target Prices

Analyst Recommendations for TherapeuticsMD (NYSEMKT:TXMD)

Receive News & Stock Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related stocks with our FREE daily email newsletter.